Default company panoramic image

BioAxone BioSciences

BioAxone specializes in regenerative medicine, with a lead drug in PII clinical development to reduce paralysis after spinal cord injury.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Cambridge, MA, USA
  • Currency USD
  • Founded May 2011
  • Employees 4
  • Website

Company Summary

BioAxone BioSciences Inc. develops proprietary technologies to treat disorders of the central nervous system (CNS). BioAxone’s lead product, Cethrin™, is disruptive technology in clinical Phase 2 development for the treatment of acute spinal cord injury (SCI), an urgent unmet need. The company has a strong preclinical pipeline for regenerative medicine and strong patent protection with over 14 issued patents and others pending.


  • Default avatar
    Lisa McKerracher

    Lisa is serial entrepreneur and a leader in translational neuroscience for bringing her research on axon regeneration forward to drug development. In 2011, Dr. McKerracher acquired the Cethrin program and created BioAxone BioSciences. Dr. McKerracher was co-recipient of the Christopher Reeve Medal for Spinal Cord Repair. Currently, Dr. McKerracher is an Adjunct Professor at McGill University and Université de Montréal. She brings CSO and CEO ex

  • Default avatar
    Kim Anderson
    Medical Writer

    Dr. Kim Anderson is an Associate Professor in the Department of Neurological Surgery at University of Miami and is focused on spinal cord injury research and bridging the gap between basic science, clinical science, and the public community living with SCI. Dr. Anderson is working with BioAxone for medical writing and preparing regulatory submissions.

  • Valerie Davisson brings 25 years of Wall Street, Corporate, and Public Accounting experienceShe supplements her Wall Street tenure with nearly a decade of corporate financial management at two S&P 100 manufacturing firms plus two years of public accounting at PriceWaterhouse, where she earned her CPA license. Valerie earned both a Master of Accounting and a BSBA in Finance at St. Louis University.

  • 19c7494f d1ef 4f6e a3ee cf5f69427f18
    Director of Regulatory and Scientific Affairs

    Dr. Bond is manages regulatory development of Cethrin. Dr. Lisa Bond has a strong science background focused on signaling pathways in mammalian cells, and she has hands-on experience with neurotrauma rehabilitation. Dr Bond earned a PhD in Clinical Biochemistry at the University of Cambridge as a Churchill Scholar and NIH Oxford-Cambridge Scholar and completed postdoctoral studies at NIH and MRC (UK).

Previous Investors

  • Default avatar
    Founder (Lisa McKerracher)
    Default avatar
    Robert Gipson (Angel Investor)